Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis

[1] Douillard JY(2010)Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 744-52

[2] Shepherd FA(2010)Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 521-9

[3] Hirsh V(2005)Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 133-44

[4] Mok T(2006)Assessing EGFR mutations N Engl J Med 354 526-8

[5] Cappuzzo F(2006)Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors J Clin Oncol 24 2158-63

[6] Ciuleanu T(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-46

[7] Stelmakh L(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-42

[8] Cicenas S(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open-label, randomised phase 3 trial Lancet Oncol 11 121-8

[9] Tsao MS(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-8

[10] Sakurada A(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-57

[1] Douillard JY(2010)Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 744-52

[2] Shepherd FA(2010)Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 521-9

[3] Hirsh V(2005)Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 133-44

[4] Mok T(2006)Assessing EGFR mutations N Engl J Med 354 526-8

[5] Cappuzzo F(2006)Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors J Clin Oncol 24 2158-63

[6] Ciuleanu T(2012)Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer(EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 239-46

[7] Stelmakh L(2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 735-42

[8] Cicenas S(2010)Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open-label, randomised phase 3 trial Lancet Oncol 11 121-8

[9] Tsao MS(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-8

[10] Sakurada A(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-57